HealthBeacon PLC HealthBeacon - HBCN - Notice of Results

Healthbeacon

25/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220825:nRSY0700Xa&default-theme=true

RNS Number : 0700X  HealthBeacon PLC  25 August 2022

Announcement Date for 2022 Half Year Results

Dublin, 25 August 2022: HealthBeacon plc ("HealthBeacon" or the "Company") and
together with its subsidiary undertakings (together the "Group"), the leading
Irish digital therapeutics company, will release Half Year Results for the six
months to 30 June 2022, on Friday, 30 September 2022.

The Company's Half Year Results Announcement and recorded Presentation will be
available on the HealthBeacon website (www.HealthBeacon.com
(https://healthbeaconltd-my.sharepoint.com/personal/kieran_lyons_healthbeacon_com/Documents/Desktop/Finance/IR/RNS/Interim%20Results/www.HealthBeacon.com)
) at 07.00am on 30 September 2022.

 

 For further details contact:
 HealthBeacon:                                   Investor.Relations@HealthBeacon.com

 Laurence Flavin

 Goodbody (Euronext Growth Sponsor and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Cathal Barry                                    +353 (0) 87 227 9281

 Paul Clifford                                   +353 (0) 87 327 2161

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops products for managing injectable medications for patients in the
home. The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics. The
Company operates across Europe, North America and the United Kingdom and
employs more than 70 people and has obtained more than 30 design and utility
patents. Peer reviewed evidence supports a 19% improvement in therapy
persistence by patients and up to 26% improvement in adherence to therapy,
which improves clinical outcomes and significantly improves efficiency in
health systems. The Company's mission is to become the world's leading digital
therapeutics platform for injectable medications.

Ends

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISESESSULEESESA